10月16日，Tempus AI盘中下跌5.05%，报67.54美元/股，成交额5597.06万美元。
消息面上，公司近期扩展与Moderna及Merck的多年合作，以支持个体化癌症疗法intismeran autogene的潜在商业化，但财务条款未披露，利好对股价提振有限。
更直接的压制来自高管减持。已披露信息显示，CEO兼董事长Eric Lefkofsky于9月22日减持726406股、9月17日减持199000股，且此前还申报拟出售20万股及25万股，内部人卖压担忧持续发酵。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.